-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Benzinga·03/24/2026 13:27:39
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from $14 to $13.